661 results on '"Dorlo, Thomas P C"'
Search Results
2. Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
3. A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
4. Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach
5. Pharmacokinetic–Pharmacodynamic Modeling and Simulation in Clinical Practice and Studies
6. Semi-mechanistic Modeling of Hypoxanthine, Xanthine, and Uric Acid Metabolism in Asphyxiated Neonates
7. Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach
8. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia
9. Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
10. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates
11. Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients
12. Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
13. Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir
14. Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP)
15. Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis
16. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication.
17. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study
18. Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir
19. Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
20. Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model.
21. Power to identify exposure‐response relationships in phase IIa pulmonary tuberculosis trials with multi‐dimensional bacterial load modeling.
22. Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
23. Comment on “Dosing implications for liposomal amphotericin B in pregnancy”
24. Pyronaridine: a review of its clinical pharmacology in the treatment of malaria
25. Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa
26. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
27. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5′-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine
28. Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
29. Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study
30. Predictability of human exposure by human‐CYP3A4‐transgenic mouse models: A meta‐analysis.
31. Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk.
32. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
33. Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of177 Lu‐PSMA‐617 in prostate cancer patients
34. A physiologically based pharmacokinetic model for [Ga-68]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
35. Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs
36. Pyronaridine : a review of its clinical pharmacology in the treatment of malaria
37. High accumulation of nivolumab in human breast milk : A case report
38. Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs
39. The use of microtracers in food-effect trials : An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib
40. Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu-PSMA-617 in prostate cancer patients
41. Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177 Lu-PSMA-617 in prostate cancer patients
42. Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach
43. Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG) : study protocol for a phase 3, non-inferiority, randomised open-label clinical trial
44. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
45. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study
46. Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT‐enhanced estimate of renal function.
47. Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling.
48. Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu‐PSMA‐617 in prostate cancer patients.
49. From Bench to Bedside: Development and Optimization of Clinical Therapies for Visceral Leishmaniasis
50. Editorial: Emerging talents in Frontiers in Pharmacology: Drug metabolism and transport 2022
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.